TOLSURA is gaining momentum in the US ● TOLSURA® now approved on...

TOLSURA is gaining momentum in the US ● TOLSURA® now approved on 8 major hospital networks and under active review at another 18 ● Continued quarter on quarter growth in new patients and script volume ● Addressable market: US$300m and expect to broaden the therapeutic use through further clinical programs - Ongoing endemic phase IIb study has potential to support an expanded therapeutic use into other fungal infections eg. coccidioidomycosis. Primary endpoint data expected to be published at IDWeek 2020, Oct 2020 - Strong evidence of a clinical benefit in select transplant patients1 - Targeting 25% itraconazole US prescription market share by end of FY22 1. SUBA-itraconazole has been deemed a safe first-line agent for the prevent of invasive fungal infections in stem cell transplant or hematological malignancy patients, B Nield, SR Larsen, S van Hal. J Antimicrob Chemother, 2019; doi:10.1093/jac/dkz303 ● Continue to explore complementary business development opportunities to expand infectious disease portfolio